Literature DB >> 9048915

The R40H mutation in a late onset type of human ornithine transcarbamylase deficiency in male patients.

A Nishiyori1, M Yoshino, H Kato, T Matsuura, R Hoshide, I Matsuda, T Kuno, S Miyazaki, S Hirose, R Kuromaru, M Mori.   

Abstract

Ornithine transcarbamylase (OTC) deficiency is an X-linked trait and is one of the most frequent of the inherited urea cycle enzyme deficiencies. Most male patients with OTC deficiency develop a hyperammonemic crisis and die in the neonatal period or in early infancy. In contrast to those patients, in some male patients the disease first becomes overt in adolescence or during the reproductive age period. In the present report, we describe six such male patients who first developed clinical signs at ages ranging from 6 to 58 years, all of whom came from a limited area of the northern part of Kyushu Island in southern Japan. The mutation analysis disclosed a R40H mutation in exon 2 of the OTC gene in each of these patients. Transmission of this mutant gene through paternal lineage as well as through maternal lineage was documented in one family. The levels of mRNA of the mutant OTC gene expressed in transfected Cos 1 cells and in the liver tissue obtained by biopsy in one patient were both similar to those of the wild-type gene. The activity of the mutant OTC was, however, decreased to a level of 28% of the wild-type OTC, and the levels of the mutant OTC protein expressed in Cos 1 cells were decreased, as assessed by western blot analysis. Apparent Km values of the mutant enzyme for ornithine (1.1 mM) and carbamylophosphate (2.0 mM) were similar to those of the wild-type enzyme. Both enzymes gave similar pH-dependency profiles, giving a maximal activity at pH 7.8-7.9. Activity of wild-type OTC expressed in Cos 1 cells did not change after five cycles of freezing and thawing, whereas that of the mutant OTC decreased to 17% by this treatment. These results suggest that deficiency is due to inactivation of the mutant OTC under certain conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048915     DOI: 10.1007/s004390050333

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  10 in total

Review 1.  Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update.

Authors:  Ljubica Caldovic; Iman Abdikarim; Sahas Narain; Mendel Tuchman; Hiroki Morizono
Journal:  J Genet Genomics       Date:  2015-05-19       Impact factor: 4.275

2.  Mutation detection in 65 families with a possible diagnosis of ornithine carbamoyltransferase deficiency including 14 novel mutations.

Authors:  S Genet; T Cranston; H R Middleton-Price
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

3.  The clinically variable R40H mutant ornithine carbamoyltransferase shows cytosolic degradation of the precursor protein in CHO cells.

Authors:  M Mavinakere; H Morizono; D Shi; N M Allewell; M Tuchman
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

4.  Late-onset ornithine transcarbamylase deficiency: a rare cause of recurrent abnormal behavior in adults.

Authors:  Masaoki Hidaka; Eiji Higashi; Takeshi Uwatoko; Kiku Uwatoko; Mayumi Urashima; Hiroshi Takashima; Yoriko Watanabe; Takanari Kitazono; Hiroshi Sugimori
Journal:  Acute Med Surg       Date:  2020-09-08

5.  Female heterozygotes for the hypomorphic R40H mutation can have ornithine transcarbamylase deficiency and present in early adolescence: a case report and review of the literature.

Authors:  Jason R Pinner; Mary-Louise Freckmann; Edwin P Kirk; Makoto Yoshino
Journal:  J Med Case Rep       Date:  2010-11-12

6.  Paternal transmission and slow elimination of mutant alleles associated with late-onset ornithine transcarbamylase deficiency in male patients.

Authors:  Sanae Numata; Eimei Harada; Yasuki Maeno; Isao Ueki; Yoriko Watanabe; Chieko Fujii; Takashi Yanagawa; Satoshi Takenaka; Toshiro Inoue; Shinkai Inoue; Terufumi Goushi; Tsutomu Yasutake; Toshihiko Mizuta; Makoto Yoshino
Journal:  J Hum Genet       Date:  2007-11-20       Impact factor: 3.172

7.  How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency?

Authors:  S Grünewald; L Fairbanks; S Genet; T Cranston; J Hüsing; J V Leonard; M P Champion
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

8.  Hyperammonemia in a Woman with Late-onset Ornithine Transcarbamylase Deficiency.

Authors:  Yudai Koya; Michihiko Shibata; Michio Senju; Yuichi Honma; Masaaki Hiura; Masahiro Ishii; Shirou Matsumoto; Masaru Harada
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271

9.  Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency.

Authors:  Koji Imoto; Masatake Tanaka; Takeshi Goya; Tomomi Aoyagi; Motoi Takahashi; Miho Kurokawa; Shigeki Tashiro; Masaki Kato; Motoyuki Kohjima; Yoshihiro Ogawa
Journal:  BMC Gastroenterol       Date:  2022-03-28       Impact factor: 3.067

10.  Common polymorphic OTC variants can act as genetic modifiers of enzymatic activity.

Authors:  Mónica Lopes-Marques; Ana Rita Pacheco; Maria João Peixoto; Ana Rita Cardoso; Catarina Serrano; António Amorim; Maria João Prata; David N Cooper; Luísa Azevedo
Journal:  Hum Mutat       Date:  2021-06-03       Impact factor: 4.878

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.